posted on 2023-03-30, 18:09authored byChristopher G. Danes, Shannon L. Wyszomierski, Jing Lu, Christopher L. Neal, Wentao Yang, Dihua Yu
Supplementary Figures 1-5 from 14-3-3ζ Down-regulates p53 in Mammary Epithelial Cells and Confers Luminal Filling
History
ARTICLE ABSTRACT
Recent progress in diagnostic tools allows many breast cancers to be detected at an early preinvasive stage. Thus, a better understanding of the molecular basis of early breast cancer progression is essential. Previously, we discovered that 14-3-3ζ is overexpressed in >40% of advanced breast cancers, and this overexpression predicts poor patient survival. Here, we examined at what stage of breast disease 14-3-3ζ overexpression occurs, and we found that increased expression of 14-3-3ζ begins at atypical ductal hyperplasia, an early stage of breast disease. To determine whether 14-3-3ζ overexpression is a decisive early event in breast cancer, we overexpressed 14-3-3ζ in MCF10A cells and examined its effect in a three-dimensional culture model. We discovered that 14-3-3ζ overexpression severely disrupted the acini architecture resulting in luminal filling. Proper lumen formation is a result of anoikis, apoptosis due to detachment from the basement membrane. We found that 14-3-3ζ overexpression conferred resistance to anoikis. Additionally, 14-3-3ζ overexpression in MCF10A cells and in mammary epithelial cells (MEC) from 14-3-3ζ transgenic mice reduced expression of p53, which is known to mediate anoikis. Mechanistically, 14-3-3ζ induced hyperactivation of the phosphoinositide 3-kinase/Akt pathway which led to phosphorylation and translocation of the MDM2 E3 ligase resulting in increased p53 degradation. Ectopic expression of p53 restored luminal apoptosis in 14-3-3ζ–overexpressing MCF10A acini in three-dimensional cultures. These data suggest that 14-3-3ζ overexpression is a critical event in early breast disease, and down-regulation of p53 is one of the mechanisms by which 14-3-3ζ alters MEC acini structure and increases the risk of breast cancer. [Cancer Res 2008;68(6):1760–7]